Literature DB >> 7705969

Humoral and cellular immune parameters in untreated and phenytoin-or carbamazepine-treated epileptic patients.

N Başaran1, F Hincal, E Kansu, A Ciğer.   

Abstract

The peripheral blood lymphocyte subsets, serum immunoglobulins (Ig A, G, M), and C3 and C4 complement protein concentrations were determined in 40 healthy subjects, 30 phenytoin-treated, 22 carbamazepine-treated and 38 untreated epileptic patients. The levels of beta-lymphocytes, IgM and C3 complement proteins were found to be significantly higher in untreated epileptics than in healthy controls (P < 0.01, P < 0.02 and P < 0.05, respectively). The absolute number of beta-lymphocytes appeared to be unaffected by phenytoin or carbamazepine treatment; however, IgM levels were significantly lower in carbamazepine-treated patients than both epileptic (P < 0.01) and healthy (P < 0.05) controls. Phenytoin-treated patients had a significant reduction in the mean IgA and IgG levels compared to healthy and epileptic controls (P < 0.05). With both drug treatments, significantly lower T-suppressor lymphocyte counts and thus higher T-helper to T-suppressor lymphocyte ratios were observed with respect to healthy and epileptic controls. Our results demonstrate that while phenytoin decreases serum IgA and IgG levels, carbamazepine reduces IgM levels significantly, and untreated epileptics show immune profiles significantly different to those of healthy subjects, suggesting that epilepsy per se may be associated with certain immune aberrations induced by antiepileptic drugs.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7705969     DOI: 10.1016/0192-0561(94)90087-6

Source DB:  PubMed          Journal:  Int J Immunopharmacol        ISSN: 0192-0561


  9 in total

1.  Oxcarbazepine-induced immunoglobulin deficiency.

Authors:  Adina Kay Knight; Charlotte Cunningham-Rundles
Journal:  Clin Diagn Lab Immunol       Date:  2005-04

2.  Hypogammaglobulinaemia with absent B lymphocytes and agranulocytosis after carbamazepine treatment.

Authors:  G P Spickett; M M Gompels; P W Saunders
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-04       Impact factor: 10.154

3.  Phenytoin promotes Th2 type immune response in mice.

Authors:  K Okada; T Sugiura; E Kuroda; S Tsuji; U Yamashita
Journal:  Clin Exp Immunol       Date:  2001-06       Impact factor: 4.330

4.  EMPACT syndrome: limited evidence despite a high-risk cohort.

Authors:  Andrew J Bishop; Maria Chang; Mario E Lacouture; Christopher A Barker
Journal:  J Neurooncol       Date:  2014-05-03       Impact factor: 4.130

5.  Immunoglobulins in children with epilepsy: the Dutch Study of Epilepsy in Childhood.

Authors:  P M C Callenbach; C M Jol-Van Der Zijde; A T Geerts; W F M Arts; C A Van Donselaar; A C B Peters; H Stroink; O F Brouwer; M J D Van Tol
Journal:  Clin Exp Immunol       Date:  2003-04       Impact factor: 4.330

6.  Effect of anti-epileptic drugs on serum level of IgG subclasses.

Authors:  Mahmoud-Reza Ashrafi; Seyed-Ahmad Hosseini; Mohammad Biglari; Sarah Abolmaali; Reza Azizi Malamiri; Hoda Mombeini; Zahra Pourpak; Narges Saladjegheh; Nima Rezaei; Azam Samadian; Asghar Aghamohammadi
Journal:  Iran J Pediatr       Date:  2010-09       Impact factor: 0.364

7.  Phenytoin as a novel anti-vitiligo weapon.

Authors:  M R Namazi
Journal:  J Autoimmune Dis       Date:  2005-11-22

8.  Is this a simple drug eruption to be discharged?

Authors:  Mucahit Emet; Ilker Akbas; Esra Senturk; Omer Faruk Elmas; Sahin Aslan
Journal:  Turk J Emerg Med       Date:  2016-06-14

Review 9.  Insights into Potential Targets for Therapeutic Intervention in Epilepsy.

Authors:  Cecilia Zavala-Tecuapetla; Manola Cuellar-Herrera; Hiram Luna-Munguia
Journal:  Int J Mol Sci       Date:  2020-11-13       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.